![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JW Boja, JL Cadet, TA Kopajtic, J Lever, HH Seltzman, CD Wyrick, AH Lewin, P Abraham and FI Carroll
Molecular Pharmacology Section, National Institutes of Health/National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland 21224, USA.
The iodine-125 analog of the dopaminergically selective cocaine analog 3 beta-(4-iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester (RT1-121) was evaluated as a probe for the dopamine transporter in rat striatum. Saturation and kinetic studies indicated that [125I]RTI-121 binds to both high and low affinity components. The Kd of the high affinity component was 0.14 +/- 0.01 nM (mean +/- standard error), whereas the low affinity component demonstrated an affinity of 1.59 +/- 0.09 nM. The corresponding numbers of striatal binding sites labeled by [125I]RTI-121 were 295 +/- 6 and 472 +/- 59 pmol/g of tissue (original wet weight), respectively. Intrastriatal injections of 6- hydroxydopamine eliminated > 90% of specific [125I]RTI-121 binding in the striatum. The pharmacological profile of specific [125I]RTI-121 binding in the rat striatum was consistent with that of the dopamine transporter. There was a strong (r = 0.98, p < 0.0001) correlation between the potencies of drugs that displaced specific [125I]RTI-121 binding and the potencies of these drugs to inhibit the uptake of [3H]dopamine. In contrast, no correlation was found for the potencies of drugs to inhibit the uptake of either [3H]norepinephrine or [3H]serotonin. Autoradiographs produced using [125I]RTI-121 demonstrated a distribution of label consistent with the distribution of dopaminergic neurons in rat brain. Because of its high affinity and high selectivity for the dopamine transporter, [125I]RTI-121 may be an extremely useful ligand for the dopamine transporter.
This article has been cited by other articles:
|
|
 |
|
  A. Heller, N. Bubula, R. Lew, B. Heller, and L. Won Gender-Dependent Enhanced Adult Neurotoxic Response to Methamphetamine following Fetal Exposure to the Drug J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 769 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chalon, L. Garreau, P. Emond, L. Zimmer, M.-P. Vilar, J.-C. Besnard, and D. Guilloteau Pharmacological Characterization of (E)-N-(3-iodoprop-2-enyl)-2beta -Carbomethoxy-3beta -(4'-methylphenyl)nortropane as a Selective and Potent Inhibitor of the Neuronal Dopamine Transporter J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 648 - 654. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Fang and O. K. Ronnekleiv Cocaine Upregulates the Dopamine Transporter in Fetal Rhesus Monkey Brain J. Neurosci., October 15, 1999; 19(20): 8966 - 8978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Zahniser, G. A. Larson, and G. A. Gerhardt In Vivo Dopamine Clearance Rate in Rat Striatum: Regulation by Extracellular Dopamine Concentration and Dopamine Transporter Inhibitors J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 266 - 277. [Abstract] [Full Text]
|
|
|
|
|
|
L.-I Tsao, B. Ladenheim, A. M. Andrews, C. C. Chiueh, J. L. Cadet, and T.-P. Su Delta Opioid Peptide [D-Ala2,D-leu5]Enkephalin Blocks the Long-term Loss of Dopamine Transporters Induced by Multiple Administrations of Methamphetamine: Involvement of Opioid Receptors and Reactive Oxygen Species J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 322 - 331. [Abstract] [Full Text]
|
|
|
|
|
|
S. R. Tella, B. Ladenheim, and J. L. Cadet Differential Regulation of Dopamine Transporter after Chronic Self-administration of Bupropion and Nomifensine J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 508 - 513. [Abstract] [Full Text]
|
|
|
|
|
|
S. R. Tella, B. Ladenheim, A. M. Andrews, S. R. Goldberg, and J. L. Cadet Differential Reinforcing Effects of Cocaine and GBR-12909: Biochemical Evidence for Divergent Neuroadaptive Changes in the Mesolimbic Dopaminergic System J. Neurosci., December 1, 1996; 16(23): 7416 - 7427. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
